Abstract: Metallothionein 1 (MT1) has been demonstrated to be an essential stress protein in maintaining physiological balance and regulating immune homeostasis. While the immunological involvement of MT1 in central nervous system disorders and cancer has been extensively investigated, mounting evidence suggests that MT1 has a broader role in inflammatory diseases and can shape innate and adaptive immunity. In this review, we will first summarize the biological features of MT1 and the regulators that influence MT1 expression, emphasizing metal, inflammation, and immunosuppressive factors. We will then focus on the immunoregulatory function of MT1 on diverse immune cells and the signaling pathways regulated by MT1. Finally, we will discuss recent advances in our knowledge of the biological role of MT1 in several inflammatory diseases to develop novel therapeutic strategies.
Introduction
Metallothionein 1 (MT1) is far more than just a "metal sponge" for detoxifying heavy metals; it is a sophisticated immunomodulator that maintains physiological balance. For decades, Metallothioneins (MTs) were primarily viewed through the lens of toxicology—proteins that bind heavy metals like zinc and copper to prevent cell damage. While their roles in the central nervous system and cancer are well-documented, their broader influence on the immune system has recently come into sharper focus.
Chronic inflammation is often a "tug-of-war" between pro-inflammatory signals and regulatory mechanisms. MT1 acts as a molecular rheostat, sensing environmental stressors—such as metal fluctuations or cytokines—and adjusting the immune response to prevent tissue damage. This review explores how MT1 shapes both innate and adaptive immunity by regulating key signaling pathways, offering a promising new spotlight for treating chronic inflammatory diseases.
Immunoregulatory Functions of MT1
MT1 influences a wide array of immune cells, acting as a critical regulator of both innate and adaptive immunity. One of its primary mechanisms is the "Zinc Switch," where MT1 sequesters or releases intracellular labile zinc (Zn²⁺) to modulate enzyme activity and transcription factors.
As illustrated above, MT1 impacts several cell types:
- Dendritic Cells: MT1 inhibits Sirt1, which in turn promotes the differentiation of FoxP3+ Regulatory T cells (Tregs).
- Macrophages: It influences the production of pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α, and supports antimicrobial activity via oxidative bursts.
- T-Cell Plasticity: MT1 is a major player in T-cell differentiation, promoting protective Tregs while suppressing pro-inflammatory Th17 and Tr1 cells. This makes it a natural brake on autoimmunity.
- Basophils/Eosinophils: By limiting free zinc, MT1 regulates calcineurin/NFAT signaling required for IL-4 production.
Signaling Pathways Regulated by MT1
Beyond direct cellular modulation, MT1 serves as a hub for several major intracellular signaling pathways. Its effects are often context-dependent, allowing it to act as either a promoter or inhibitor of inflammation depending on the tissue type and the specific inflammatory context.
Key pathways regulated by MT1 include:
- STAT1/3: MT1 can inhibit the phosphorylation of STAT proteins, thereby suppressing the differentiation of Th17 and Tr1 cells and reducing the production of IL-10 or IL-17.
- NF-κB: MT1 interacts with the p50 and p65 subunits. While it can promote NF-κB activity in some contexts (leading to apoptosis resistance), it can also inhibit IκBα degradation to prevent tumorigenesis.
- Akt and Wnt/β-Catenin: MT1 acts as a brake on these pathways, which are often dysregulated in chronic inflammation and cancer.
Clinical Implications and Therapeutic Potential
Research using MT1/2-deficient mouse models and clinical data has highlighted the protein's therapeutic potential across various diseases:
- Rheumatoid Arthritis (RA): MT1 is significantly upregulated in RA patients. In mouse models, local administration of MT1 dramatically suppressed joint inflammation by shifting the Th17/Treg balance.
- Multiple Sclerosis (MS): MT1/2-deficient mice suffer from much more severe demyelination and axonal damage. Conversely, treating these mice with MT protein can ameliorate the disease.
- Neuroprotection: Delivering human MT1A directly to mitochondria has been shown to rescue dopaminergic neurons and improve movement in Parkinson’s disease models.
- Infectious Disease: MT1 is essential for the "oxidative burst" in macrophages. It also participates in "nutritional immunity," where the host hides essential metals from invading pathogens to starve them.
Limitations and Future Directions
Despite its promise, several critical gaps remain. It is still unclear whether MT1’s most important immune functions happen inside the cell or if it acts as a secreted signaling molecule that binds to surface receptors. Furthermore, humans have 18 different MT1 isoforms; future research must isolate their unique contributions. Developing isoform-specific models and effective delivery systems for MT1-based therapies are the next frontiers in utilizing this protein as a precision medicine tool.
Summary updated